SS-31 30mg

Researchers comparing where to buy SS-31 for research need a documentation-first view, not a consumer buying guide. SS-31, also known as elamipretide in scientific databases, is discussed in peptide and mitochondrial research literature as a synthetic tetrapeptide associated with cardiolipin and mitochondrial bioenergetics [1] [2] [3]. This Pure Lab Peptides guide keeps the focus on research-use-only labeling, COA review, analytical testing, literature interpretation, and technical procurement.

• SS-31 is indexed as elamipretide, MTP-131, SS31, and Bendavia in scientific databases, with PubChem listing the free-base molecular formula as C32H49N9O5 [1] [2].
• Published literature commonly classifies SS-31 as a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt refers to dimethyltyrosine [3].
• Mitochondrial research literature has examined SS-31 in relation to cardiolipin, lipid-bilayer interaction, cytochrome c/cardiolipin systems, ATP-related bioenergetics, and mitochondrial protein interaction mapping [4] [5] [6] [7].
• HPLC can support peptide purity review, while LC-MS or LC-HRMS can support molecular identity and impurity characterization when paired with suitable reference data [18] [19] [20].
• Published literature informs research context; it does not establish suitability or outcomes for an RUO product in clinical or consumer use.
• This page is for the 30 mg catalog presentation. The listed vial amount identifies the product strength; it is not an experimental instruction.

Fast Answer: What Should Researchers Check Before They Buy SS-31 for Research?

Researchers evaluating where to buy SS-31 for research should first review RUO labeling, compound identity, batch-specific COA, HPLC purity data, LC-MS identity support, and lot traceability. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Scientific literature describes SS-31 as elamipretide/MTP-131, a mitochondrial research peptide [2] [3].

Match the Product to Its Analytical Record

Before selecting SS-31, compare the compound name, vial amount, lot number, and test methods across the listing and certificate of analysis. A paper about elamipretide establishes research context; it does not establish the identity or purity of a particular vial.

What Documentation Should Come First When Teams Buy SS-31 for Research?

The first documents to review are the product listing, certificate of analysis, analytical testing records, vial label, and lot-specific identifiers. FDA analytical guidance treats analytical procedure documentation as part of demonstrating identity, quality, purity, and related product-quality attributes in regulated settings; RUO procurement teams can borrow the same documentation mindset without treating the material as a clinical product [24] [29].

A strong SS-31 research material listing should make the compound name, synonym set, lot number, COA availability, and analytical method references easy to reconcile.

Why RUO Labeling Matters Before Supplier Evaluation?

RUO labeling identifies material intended for laboratory research. Review that designation alongside analytical documentation, batch verification, and laboratory handling records.

For SS-31, that boundary matters because academic literature includes mitochondrial, cellular, cardiovascular research, and human-study categories. Those literature categories do not change the intended status of an RUO research compound.

What Is SS-31 in Peptide Research Literature?

SS-31 is a short synthetic peptide also known as elamipretide and MTP-131 in scientific indexing systems [1] [2]. PubChem identifies elamipretide as C32H49N9O5, and peptide literature commonly describes it as a tetrapeptide sequence containing D-arginine, dimethyltyrosine, lysine, and phenylalanine amide [1] [3].

Compound Identity and Tetrapeptide Classification

A tetrapeptide contains four amino acid residues. Review literature describes SS-31 with the sequence D-Arg-Dmt-Lys-Phe-NH2, which supports sequence and molecular identity review [3].

For documentation review, the key is consistency. “SS-31,” “peptide SS-31,” “elamipretide,” “MTP-131,” “SS31,” and “SS 31” should point to the same intended research compound across the product page, COA, and batch records.

How Elamipretide and MTP-131 Relate to SS-31?

Elamipretide and MTP-131 are literature and database synonyms associated with SS-31 [2]. These names appear in mechanistic research, mitochondrial bioenergetics literature, and official database indexing, so procurement teams should expect supplier documentation to reconcile them clearly [1] [2].

A mismatch between synonym, label, and COA can create ambiguity. A clean research record should reduce that ambiguity before any SS-31 research material is selected.

Why Sequence Documentation Matters for Peptide Identity?

Sequence documentation helps confirm that the intended synthetic peptide corresponds to the compound described in literature and databases. For SS-31, sequence review is especially useful because modified residues and terminal amide notation can affect molecular identity records [3].

Sequence alone is not a complete verification package. It should be paired with molecular formula, molecular weight, analytical testing, lot traceability, and batch-specific COA documentation.

SS-31 Research Material Documentation

Three records answer different questions: compound databases describe identity, published studies describe the models investigated, and the lot-specific COA reports analytical results for the tested sample. Compare these records without treating one as a substitute for another.

Research Context and Batch Identity

SS-31 studies discuss mitochondrial models. The material offered here is for laboratory research only, and its batch documentation must be assessed independently of those published findings.

What a Research Material Listing Should Communicate?

A research material listing should communicate compound name, synonym consistency, lot number, COA availability, purity method, identity method, storage documentation, and RUO labeling. ISO/IEC 17025 emphasizes competent laboratory testing and valid results in testing and calibration contexts, which supports the value of clear test reports and traceable documentation for laboratory review [27].

For a vial-based research material, the label, COA, and product listing should tell the same story.

Mitochondrial Research Background for SS-31

Published SS-31 literature examines cardiolipin, the inner mitochondrial membrane, mitochondrial bioenergetics, and electron transport chain function [4] [5] [6] [7]. Mitochondria contain inner membrane systems where electron transport and oxidative phosphorylation are central to ATP production [12] [13].

Cardiolipin and Inner Membrane Research Context

Cardiolipin is a phospholipid strongly associated with mitochondrial membranes and respiratory-chain organization [8] [9]. Reviews describe cardiolipin as important for mitochondrial protein assembly, membrane structure, electron transport chain complexes, and supercomplex organization [8] [10].

SS-31 research often intersects with cardiolipin because several studies describe SS-31 interaction with cardiolipin-containing systems or lipid bilayers [5] [6].

How Mitochondrial Bioenergetics Frames Study Design?

Mitochondrial bioenergetics refers to study models that examine electron flow, membrane potential, oxygen consumption, ATP production, and redox-linked mitochondrial parameters. NCBI Bookshelf summarizes oxidative phosphorylation as electron transfer through inner-membrane complexes coupled to proton-gradient-driven ATP synthesis [12] [13].

SS-31 studies have evaluated cardiolipin-linked respiration, cytochrome c/cardiolipin interaction, and ATP-related outputs in model systems [6] [14].

ATP Production as a Research Endpoint

ATP production is a measurable endpoint in mitochondrial bioenergetics research. The electron transport chain and ATP synthase are core elements of oxidative phosphorylation, and ATP synthase uses the proton gradient across the inner mitochondrial membrane to form ATP [12].

ATP-related measurements in SS-31 literature are model-specific endpoints, not evidence of outcomes for a supplied research-only product.

SS-31 Mechanism of Action: Membrane and Protein Studies

The cited studies examine membrane interaction, cardiolipin-associated systems, and mitochondrial protein contacts. These are distinct experimental approaches, not a single measurement or a guarantee of results in another model.

How SS-31 Binds Within Mitochondrial Models?

Published studies report SS-31 interaction with cardiolipin-containing membranes, lipid bilayers, and mitochondrial protein environments [5] [6] [7]. A 2020 PNAS study used chemical cross-linking with mass spectrometry to map SS-31 mitochondrial protein interaction patterns, including proteins linked to ATP production and oxidative phosphorylation pathways [7].

The protein-interaction findings depend on the experimental system and analytical workflow used in that study; they do not establish a result for an independently sourced research material.

Electron Transport Chain Function in Published Models

The electron transport chain includes complexes and carriers in the inner mitochondrial membrane that transfer electrons and contribute to a proton gradient used by ATP synthase [12]. Reviews of mitochondrial reactive oxygen species also describe ETC function as closely linked to redox biology and oxidative stress models [11].

SS-31 literature connects to this area through cardiolipin, cytochrome c/cardiolipin interaction, and model-specific mitochondrial bioenergetics endpoints [6] [7].

Research Applications in Cellular and Cardiovascular Research Contexts

The following research applications are grouped by experimental context: cellular and mitochondrial models, cardiovascular research, bioenergetic assays, and oxidative stress measurements. Model type and measured endpoint matter when comparing findings.

What Oxidative Stress Models Can Show?

Oxidative stress models can show how a defined experimental system responds under selected laboratory conditions. Reviews describe mitochondrial reactive oxygen species as linked to ETC function, redox signaling, and stress biology in model systems [11].

Oxidative stress measurements in a defined model cannot establish the performance of every SS-31 preparation or be assumed to predict findings in a different experimental system.

How Mitochondrial Dysfunction Is Framed in Studies?

Mitochondrial dysfunction is a literature concept used to describe altered mitochondrial structure, respiration, redox balance, or bioenergetic parameters in defined study systems [8] [11] [13]. SS-31 research has appeared in ex vivo, cellular, and preclinical studies that examine mitochondrial function and cardiolipin-linked pathways [14] [15] [16].

These findings remain specific to the models, materials, and endpoints examined in the cited studies.

Interpreting the SS-31 Research Evidence

Published SS-31 literature spans mechanistic studies, cellular models, preclinical studies, ex vivo research, reviews, and human studies involving materials outside the scope of RUO product use [4] [6] [7] [15] [17]. The table separates study types and explains their contributions to research review.

Compare Evidence by Model and Method

Database records, in vitro experiments, ex vivo studies, preclinical investigations, and human studies answer different questions. They are not a fixed sequence in which one automatically validates another. Compare the material characterized, model, controls, analytical methods, and endpoints before drawing connections between studies.

What Study Findings Can and Cannot Support?

Study findings can support statements about what researchers examined in a specific model. They cannot support claims that an RUO material is intended for consumer, clinical, veterinary, or wellness contexts.

Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials [17].

Published Findings and the Material Supplied

Published findings describe the materials and conditions used by the investigators. A supplier’s analytical report describes a tested sample from a particular lot. Neither record alone establishes that a separate experiment will reproduce a published result.

COA Documentation for SS-31 Peptide Review

A certificate of analysis is a batch-specific record that should identify the material, lot, date, test methods, and reported values. FDA analytical guidance discusses documentation of analytical procedures and validation data to support identity, quality, purity, and related attributes in regulated analytical contexts [24] [29].

What a Certificate of Analysis Should Identify?

For SS-31, a COA should identify the compound name, synonym if applicable, lot number, testing date, purity method, identity method, and issuing laboratory. It should also make clear whether the reported data correspond to the same batch shown on the label and product listing.

A COA is most useful when it is batch-specific. A generic certificate gives less procurement value because it may not connect to the vial under review.

How Lot-Specific COA Review Supports Procurement?

Lot-specific COA review allows laboratory buyers to match the product listing to a defined batch record. NIST explains metrological traceability as a measurement result’s relationship to a reference through a documented chain; that traceability mindset is useful when reviewing test records, reference materials, and batch-level documentation [28].

For SS-31 procurement, the key question is whether the COA, label, and supplier documentation point to the same lot.

Why COA Dates and Batch Details Matter?

Dates and batch details help establish whether the analytical record is current for the listed material. ISO/IEC 17025 emphasizes valid laboratory results and competent testing operations, and that principle supports careful review of testing records and report details [27].

If a COA lacks batch linkage or method information, research teams should treat it as incomplete documentation.

Analytical Testing and Peptide Identity Verification

Analytical testing can support purity, identity, and impurity review. It cannot, by itself, replace clear labeling or batch documentation.

Use this numbered lab-test verification workflow:

1. Verify the compound name, synonym set, lot number, and vial label against the product-page documentation.
2. Review the batch-specific certificate of analysis.
3. Check whether the purity testing method is listed.
4. Confirm whether identity testing is supported by LC-MS, LC-HRMS, or another suitable analytical method.
5. Review chromatogram or mass data when available.
6. Check the COA date, issuing laboratory, and batch linkage.
7. Document storage and handling requirements in a laboratory record.

How HPLC Supports Peptide Purity Review?

HPLC is widely used for peptide analysis and separation, including reversed-phase and other chromatographic modes [18]. In an SS-31 COA review, HPLC purity data can help show whether the main chromatographic peak is reported in relation to detectable related peaks under the stated method.

HPLC does not fully prove identity on its own. It is strongest when paired with identity-focused analytical data.

How LC-MS Supports Molecular Identity Review?

LC-MS and LC-HRMS can support peptide identity and impurity characterization by combining chromatographic separation with mass-based information [19] [20]. For synthetic peptides, LC-MS workflows can help characterize impurities and confirm molecular features when the method is suitable for the compound and reference data are available [20] [21].

For SS-31, LC-MS support should be reviewed alongside molecular formula, sequence documentation, and lot-specific records.

What Chromatogram and Mass Data Add?

A chromatogram shows retention-time and peak-area information under a stated method, while mass data can support molecular identity review through mass-to-charge information [18] [19]. USP <621> describes general chromatography procedures, definitions, calculations, and system suitability concepts relevant to chromatographic review [26].

For procurement teams, the practical value is cross-checking: does the analytical data align with the COA, label, and compound identity?

Purity, Synthesis, and Lyophilized Peptide Documentation

SS-31 is a synthetic peptide, so synthesis records and purification documentation matter for research review. Solid-phase peptide synthesis is a central method in peptide chemistry, where a growing peptide chain is assembled on a resin support and then released after chain assembly [22].

Why Synthetic Peptide Source Records Matter?

Synthetic peptide source records can help laboratory teams evaluate whether the material has a coherent identity and quality record. Peptide synthesis can introduce related impurities, which is why analytical review is important for synthetic peptide characterization [20] [21].

A supplier does not need to publish proprietary manufacturing details on a product page. It should still provide enough documentation for research buyers to evaluate identity, purity, and lot traceability.

How Lyophilized Powder Details Support Handling Review?

Lyophilized powder documentation can support laboratory storage and handling records. Freeze drying, also called lyophilization, removes water from a frozen sample through sublimation and desorption, and is often discussed in relation to solid-state stability of proteins and peptides [23] [30].

Record the supplier’s stated storage conditions and the lot identifier alongside the laboratory’s receipt and storage records.

Vial Labeling and Batch Traceability Review

A vial label is part of the documentation chain. It should align with the product listing, COA, and any batch-specific analytical records.

What Vial Labels Should Match Across Documents?

The vial label should match the compound name, lot number, catalog identifier when present, and RUO labeling. If the label says SS-31 and the COA says elamipretide, the documentation should explain that these refer to the same research peptide through recognized synonym records [1] [2].

This is especially important for abbreviations. SS-31, SS31, and SS 31 should not create separate identity records.

How Batch Numbers Connect Listing, COA, and Records?

Batch numbers connect the product listing to the COA and any supporting analytical data. When batch identifiers are missing, the buyer cannot easily determine whether the test data apply to the listed research material.

Batch traceability is not a marketing feature. It is a documentation control.

SS-31 Supplier Documentation Comparison

Researchers evaluating a peptide online should compare suppliers by documentation quality, not by claim-heavy language. The matrix below compares labeling, lot-specific analytical evidence, and traceability.

What Research Buyers Should Compare Across Suppliers?

Compare documentation availability, not unsupported claims. Useful supplier documentation includes a batch-specific COA, method references, label consistency, and a clear research-only designation.

For SS-31, distinguish compound-level mitochondrial and cardiolipin research from the analytical evidence supplied for an individual lot.

How Product Listing Details Support Technical Procurement?

Product listing details help procurement teams decide whether a material is suitable for laboratory review. Useful listing details include compound name, synonym set, research category, physical format, lot linkage, testing availability, and storage documentation.

A listing should not rely on broad claims. The more precise approach is to show the documentation chain.

Procurement Review Checklist Before Teams Buy SS-31 for Research

Use this checklist to reconcile the analytical record with the material being evaluated.

• Verify that the product is labeled for research use only.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are supported by analytical testing.
• Check that the lot number on the COA matches the product documentation.
• Compare compound name, molecular formula, molecular weight, and sequence across documentation.
• Assess whether the product page avoids consumer-facing or clinical-use product claims.
• Document storage and handling conditions in a laboratory record.

Documentation Signals That Support Selection

Strong documentation signals include a clear RUO statement, synonym consistency, batch-specific COA, HPLC purity information, LC-MS identity support, lot number alignment, and storage documentation. Peptide reference-standard literature also emphasizes vialing, lyophilization, analytical testing, and stability studies as quality-supporting concepts for peptide standards [30].

These signals do not make biological claims. They support technical procurement review.

Red Flags for Non-RUO Product Positioning

Red flags include consumer outcome language, clinical-use framing, unsupported product-performance statements, and missing analytical documentation. A product page that emphasizes claims over COA review is less useful for laboratory procurement.

For research teams comparing where to buy SS-31 for research, documentation quality should come before promotional language.

Common Questions About SS-31 Evidence

Published findings describe the researchers’ experimental materials and conditions, not product-use guidance for an independently supplied RUO material.

Evidence from one model does not automatically transfer to another. Human-study literature remains outside the scope of RUO product use [17].

A purity percentage does not prove complete compound identity. HPLC purity review should be paired with LC-MS or another identity-supporting method when available [18] [19].

A COA should be batch-specific. Without lot linkage, a certificate has limited value for procurement review.

Mitochondrial pathway relevance provides context for published experiments; it does not establish outcomes for a supplied product.

Next Steps for Research Documentation Review

For research teams comparing peptide suppliers, prioritize COA availability, transparent labeling, lot-level documentation, and analytical testing support. Review the product-page documentation, COA details, and RUO labeling before evaluating SS-31 for laboratory research.

FAQs

What is SS-31 in research literature?

SS-31 is described in research literature as a synthetic tetrapeptide also known as elamipretide or MTP-131. It is discussed in mitochondrial research contexts, including cardiolipin-associated models and peptide identity documentation [1] [2] [3]. The lot-specific analytical record is separate from these compound-level literature descriptions.

What should researchers review before they buy SS-31 for research?

Researchers should review RUO labeling, COA documentation, lot traceability, peptide identity data, and supplier documentation before they buy SS-31 for research. The review should also compare vial labeling, batch-specific records, and analytical testing support. A catalog amount should be treated only as a listing specification, not as practical product guidance.

In what form is SS-31 supplied for laboratory research?

The product listing identifies the physical format of the research material; check it against the vial label and lot documentation. For peptide vials, researchers should compare the vial label, compound name, lot number, storage documentation, and COA details. Lyophilized peptides still require documentation-focused peptide handling review, including label consistency and batch-specific traceability.

What role does mitochondrial research play in SS-31 literature?

Mitochondrial research provides the main context for SS-31 literature. Researchers have examined SS-31 alongside the mitochondrion, cardiolipin, mitochondrial bioenergetics, cellular energy models, and ATP-related study endpoints [4] [6] [7]. Interpret these endpoints within the model and methods of the individual study.

How should researchers interpret SS-31 pathway language?

Interpret SS-31 pathway terminology within defined research models. Terms such as mitochondria-targeting peptide, mitochondrial permeability transition pore, electron transport chain, and cellular respiration describe research settings, not demonstrated outcomes for a supplied product.

Why does RUO labeling matter for SS-31 product pages?

The SS-31 material sold here is intended only for laboratory research. Published work involving elamipretide does not make this catalog material a medicine or establish suitability for human or veterinary use.

---

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Hazel H. Szeto

Author profile: ORCID

Hazel H. Szeto’s published work addresses cardiolipin, mitochondrial membrane biology, and peptide-focused mitochondrial research, including cardiolipin-associated models, mitochondrial bioenergetics, and sequence-defined tetrapeptides. The selected publications provide background for interpreting SS-31 research.

Selected publications:

• A review on cardiolipin-targeted peptide discovery and mitochondrial research context — Clinical Pharmacology & Therapeutics, 2014. DOI: 10.1038/clpt.2014.174. PMID: [25188726].
• A peer-reviewed study on SS-31, cardiolipin, and cytochrome c research models — British Journal of Pharmacology, 2014. DOI: 10.1111/bph.12468. PMID: [24134698].

Juan D. Chavez

Author profile: Google Scholar

Juan D. Chavez’s published work involves chemical cross-linking, mass spectrometry, and mitochondrial protein interaction mapping. His SS-31 publication examines mitochondrial protein interactions, while his broader analytical work provides context for model-specific pathway interpretation.

Selected publications:

• Mitochondrial protein interaction landscape of SS-31 — Proceedings of the National Academy of Sciences, 2020. DOI: 10.1073/pnas.2002250117. PMID: [32554501].
• Chemical cross-linking with mass spectrometry: a tool for systems structural biology — Current Opinion in Chemical Biology, 2019. DOI: 10.1016/j.cbpa.2018.08.006. PMID: [30172868].

REFERENCES

1. National Center for Biotechnology Information. Elamipretide compound record. PubChem, NIH. CID 11764719.
2. IUPHAR/BPS Guide to Pharmacology. Elamipretide ligand record. GtoPdb Ligand ID 14276.
3. Tung C, et al. Elamipretide structure and mitochondrial mechanism review. Peer-reviewed review article. 2025.
4. Szeto HH, Birk AV. Review of cardiolipin-targeted SS peptide discovery. Clinical Pharmacology & Therapeutics. 2014. DOI: 10.1038/clpt.2014.174. PMID: 25188726.
5. Mitchell W, et al. SS-31 lipid-bilayer interaction and membrane electrostatics study. Journal of Biological Chemistry. 2020. DOI: 10.1074/jbc.RA119.012094. PMID: 32273339.
6. Birk AV, et al. Cardiolipin and cytochrome c/cardiolipin interaction study involving SS-31. British Journal of Pharmacology. 2014. DOI: 10.1111/bph.12468. PMID: 24134698.
7. Chavez JD, et al. Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences. 2020. DOI: 10.1073/pnas.2002250117. PMID: 32554501.
8. Paradies G, et al. Cardiolipin and mitochondrial function review. Cells. 2019. PMID: 31315173.
9. Claypool SM. Cardiolipin and mitochondrial carrier protein assembly review. Biochimica et Biophysica Acta. 2009. PMID: 19422785.
10. Raja V, Greenberg ML. Cardiolipin in cellular metabolism review. Chemistry and Physics of Lipids. 2014. PMID: 24445246.
11. Nolfi-Donegan D, Braganza A, Shiva S. Mitochondrial electron transport chain and redox biology review. Redox Biology. 2020.
12. Ahmad M, Wolberg A, Kahwaji CI. Biochemistry, Electron Transport Chain. StatPearls, NCBI Bookshelf. Updated 2023.
13. Cooper GM. Mitochondria overview. The Cell: A Molecular Approach, NCBI Bookshelf. 2000.
14. Birk AV, et al. SS-31 and cardiolipin-linked mitochondrial model study. Journal of the American Society of Nephrology. 2013. PMID: 23813215.
15. Chatfield KC, et al. Ex vivo cardiovascular mitochondrial research involving elamipretide. JACC: Basic to Translational Science. 2019. DOI: 10.1016/j.jacbts.2018.12.005. PMID: 31061916.
16. Pharaoh G, et al. Adenine nucleotide translocator and SS-31 mitochondrial research study. GeroScience. 2023. DOI: 10.1007/s11357-023-00861-y. PMID: 37462785.
17. Karaa A, et al. Human-study literature involving elamipretide in mitochondrial research context. Neurology. 2023. DOI: 10.1212/WNL.0000000000207402. PMID: 37268435.
18. Mant CT, Chen Y, Yan Z, Popa TV, Kovacs JM, Mills JB, Tripet BP, Hodges RS. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007. DOI: 10.1007/978-1-59745-430-8_1. PMID: 18604941.
19. Zeng K, et al. LC-HRMS for peptide quality-control characterization. AAPS Journal. 2015. PMID: 25716148.
20. Lian Z, et al. Synthetic peptide LC-MS characterization workflow review. Journal of the American Society for Mass Spectrometry. 2021. PMID: 34110145.
21. De Spiegeleer B, Vergote V, Pezeshki A, Peremans K, Burvenich CPG. Synthetic peptide impurity profiling by liquid chromatography and mass spectrometry. Analytical Biochemistry. 2008. DOI: 10.1016/j.ab.2008.02.014. PMID: 18342612.
22. Stawikowski M, Fields GB. Introduction to peptide synthesis. Current Protocols in Protein Science. 2002/2013 archive.
23. Roy I, Gupta MN. Freeze-drying of proteins: emerging concerns. Biotechnology and Applied Biochemistry. 2004. PMID: 15032737.
24. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA Guidance. 2024.
25. U.S. Food and Drug Administration. Q14 Analytical Procedure Development. FDA Guidance. 2024.
26. United States Pharmacopeia. USP <621> Chromatography. USP Harmonized General Chapter. 2021.
27. International Organization for Standardization. ISO/IEC 17025 testing and calibration laboratories. ISO official resource.
28. National Institute of Standards and Technology. Metrological traceability resource. NIST official resource.
29. U.S. Food and Drug Administration. Analytical procedures and methods validation guidance. FDA Guidance. 2015/2020 page.
30. McCarthy D, Han Y, Carrick K, Atouf F. Reference standards to support quality of synthetic peptide products. Pharmaceutical Research. 2023. PMID: 36949371.

---

Research Disclaimer

This material is supplied for in vitro laboratory research only. It is not for human or veterinary use. The studies cited describe the authors’ experimental materials, methods, and findings; they do not establish safety, efficacy, or suitability of this catalog product for any non-research purpose. Review the original studies and the lot-specific analytical documentation independently.